Industry
Biotechnology
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
December 21, 2023 | 3:37 pm
Portfolio Pulse from Henry Khederian
December 21, 2023 | 1:50 pm
Portfolio Pulse from Benzinga Newsdesk
December 21, 2023 | 1:50 pm
Portfolio Pulse from Benzinga Newsdesk
December 21, 2023 | 1:05 pm
Portfolio Pulse from Benzinga Insights
December 20, 2023 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
November 10, 2023 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
November 10, 2023 | 12:31 pm
Portfolio Pulse from Benzinga Insights
November 10, 2023 | 12:02 pm
Portfolio Pulse from Benzinga Insights
November 09, 2023 | 2:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.